NEW YORK (GenomeWeb News) – Proteome Sciences today announced Takeda Pharmaceuticals has extended a contract to use PS Biomarker Services for the development of mass spectrometry-based assays for disease-related proteins.
Financial and other terms of the deal were not disclosed.
In a statement, Proteome Sciences said it will apply its capabilities in the discovery and validation of peptide and protein biomarkers and in assay development for research covered by the deal.
The firms originally partnered in 2009 to use the PS Biomarker Services and Proteome Sciences' isobaric Tandem Mass Tags for a preclinical study.